Group of Chinese researchers retrospectively analysed clinical data of patients infected with SARS-CoV-2. In paper published in „Clinical Infectious Diseases”…
In journal “Expert Opinion on Biological Therapy” was published article in which overall survival (OS) of metastatic melanoma patients was…
Cooperation and concentration of scientific potential is necessary for creating and implementing innovations. Following this thought, the company Pharmfactor Sp.…
Results of the newest research published in the scientific journal Science indicate, that organisms of individuals who have recovered from…
Cooperation with the Institute of Immunology and Experimental Therapy on development projects of TFX
With the start of 2021 Biomedycyna Polska S. A. group has begun a cooperative research and development project with the…
Aprotinin is a drug that can help in the fight against COVID-19, according to scientists from the University of Kent,…
Pharmfactor (belonging to the corporate group led by Biomedycyna Polska S.A.) has finalized the patent application submission process with the…
Biomedycyna Polska S.A., an active business entity with a mission of perpetual contribution to the availability of effective solutions used in treatment…
TFX Pharma is one of the biotechnological companies belonging to the Biomedycyna Polska S. A. corporate group. The company is…
In March of 2020 Biomedycyna Polska S. A. group began aresearch collaboration with the Wrocław University of Environmental and Life…